vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to Hold at Zacks Research

vTv Therapeutics (NASDAQ:VTVT) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

Several other research analysts have also weighed in on VTVT. Wall Street Zen raised vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Weiss Ratings upgraded vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. BTIG Research reiterated a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Finally, Evercore started coverage on vTv Therapeutics in a research note on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $32.76 on Thursday. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00. The stock has a market capitalization of $129.07 million, a price-to-earnings ratio of -35.23 and a beta of 0.27. The stock has a fifty day moving average of $34.70 and a 200-day moving average of $35.04.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44. The firm had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million. As a group, equities analysts forecast that vTv Therapeutics will post -2.19 EPS for the current year.

Institutional Trading of vTv Therapeutics

Several institutional investors have recently added to or reduced their stakes in VTVT. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics during the fourth quarter valued at about $221,000. 683 Capital Management LLC purchased a new stake in vTv Therapeutics during the fourth quarter valued at about $731,000. Geode Capital Management LLC boosted its position in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP boosted its position in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the period. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.